Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma
NCT02558816Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Oct 2015
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of venetoclax in mantle cell lymphoma (MCL), sponsored by CHU de Nantes. Started Oct 2015; status: completed.
02
Drugs
venetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02558816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02558816.